Press releases

Began specific clinical research in collaboration with the University of Tokyo on long-term intake of high doses of NMN.

Mirailab Bioscience, Inc. (Head Office: Chuo-ku, Tokyo; Representative Director: Megumi Tanaka), in collaboration with the University of Tokyo National University Corporation (Professor Toshimasa Yamauchi and Lecturer Masaki Igarashi of the Department of Diabetes and Metabolism, Faculty of Medicine, University of Tokyo Hospital, and others), has started a specific clinical study on the effects of high-dose nicotinamide mononucleotide (NMN) on aging in elderly subjects. (Professor Toshimasa Yamanouchi, Professor and Lecturer Masaki Igarashi, et al.

Click here for the press release.

■For more information, please contact
Mirailab Bioscience, Inc.